Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome.

Fragile X syndrome (FXS), a common inherited form of intellectual disability with learning deficits, results from a loss of fragile X mental retardation protein (FMRP). Despite extensive research, treatment options for FXS remain limited. Since FMRP is known to play an important role in adult hippocampal neurogenesis and hippocampus-dependent learning and FMRP regulates the adult neural stem cell fate through the translational regulation of glycogen synthase kinase 3β (GSK3β), we investigated the effects of a GSK3β inhibitor, SB216763, on Fmr1 knockout mice (Fmr1 KO). We found that the inhibition of GSK3β could reverse the hippocampus-dependent learning deficits and rescue adult hippocampal neurogenesis at multiple stages in Fmr1 KO mice. Our results point to GSK3β inhibition as a potential treatment for the learning deficits seen in FXS.

[1]  E. Berry-Kravis,et al.  Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond , 2012, Neuropsychopharmacology.

[2]  A. Mortazavi.  Correction to “Fragile X Syndrome” , 2011 .

[3]  Min Zhang,et al.  Involvement of the Glycogen Synthase Kinase-3 Signaling Pathway in TBI Pathology and Neurocognitive Outcome , 2011, PloS one.

[4]  P. Jin,et al.  RNA-Binding Protein FXR2 Regulates Adult Hippocampal Neurogenesis by Reducing Noggin Expression , 2011, Neuron.

[5]  C. B. Smith,et al.  Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. , 2011, The international journal of neuropsychopharmacology.

[6]  P. Jin,et al.  Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning , 2011, Nature Medicine.

[7]  P. Spano,et al.  Glycogen synthase kinase‐3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production , 2011, Journal of neurochemistry.

[8]  M. Bear,et al.  Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome , 2011, Proceedings of the National Academy of Sciences.

[9]  Mark F Bear,et al.  Toward fulfilling the promise of molecular medicine in fragile X syndrome. , 2011, Annual review of medicine.

[10]  M. Celeste Simon,et al.  O2 regulates stem cells through Wnt/β-catenin signalling , 2010, Nature Cell Biology.

[11]  Xinyu Zhao,et al.  Epigenetic regulation of neuronal dendrite and dendritic spine development , 2010, Frontiers in Biology.

[12]  Eun-Mi Hur,et al.  GSK3 signalling in neural development , 2010, Nature Reviews Neuroscience.

[13]  C. Portera-Cailliau,et al.  Delayed Stabilization of Dendritic Spines in Fragile X Mice , 2010, The Journal of Neuroscience.

[14]  P. Jin,et al.  MicroRNA miR‐137 Regulates Neuronal Maturation by Targeting Ubiquitin Ligase Mind Bomb‐1 , 2010, Stem cells.

[15]  P. Jin,et al.  Epigenetic regulation of miR-184 by MBD1 governs neural stem cell proliferation and differentiation. , 2010, Cell stem cell.

[16]  F. Gage,et al.  New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? , 2010, Nature Reviews Neuroscience.

[17]  P. Jin,et al.  Fragile X Mental Retardation Protein Regulates Proliferation and Differentiation of Adult Neural Stem/Progenitor Cells , 2010, PLoS genetics.

[18]  R. Jope,et al.  GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism , 2010, PloS one.

[19]  J. Sweatt,et al.  Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. , 2010, Biochemical pharmacology.

[20]  J. Parent,et al.  The Developmental Stage of Dentate Granule Cells Dictates Their Contribution to Seizure-Induced Plasticity , 2010, The Journal of Neuroscience.

[21]  L. Saksida,et al.  A Functional Role for Adult Hippocampal Neurogenesis in Spatial Pattern Separation , 2009, Science.

[22]  B. Oostra,et al.  FMR1: a gene with three faces. , 2009, Biochimica et biophysica acta.

[23]  Li-Huei Tsai,et al.  Disrupted in Schizophrenia 1 Regulates Neuronal Progenitor Proliferation via Modulation of GSK3β/β-Catenin Signaling , 2009, Cell.

[24]  R. Jope,et al.  Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential , 2009, Neuropharmacology.

[25]  Allan L Reiss,et al.  Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies. , 2009, Developmental disabilities research reviews.

[26]  Xinyu Zhao,et al.  Endogenous Matrix Metalloproteinase (MMP)‐3 and MMP‐9 Promote the Differentiation and Migration of Adult Neural Progenitor Cells in Response to Chemokines , 2008, Stem cells.

[27]  S. Warren,et al.  Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function , 2008, Neuron.

[28]  E. Flori,et al.  GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. , 2008, Cellular signalling.

[29]  Chris I. De Zeeuw,et al.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice , 2008, Neurobiology of Disease.

[30]  A. Hsu,et al.  Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. , 2008, American journal of physiology. Heart and circulatory physiology.

[31]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[32]  S. Warren,et al.  The pathophysiology of fragile x syndrome. , 2007, Annual review of genomics and human genetics.

[33]  Hungwen Chen,et al.  Thiazolidinediones Modulate the Expression of β-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor γ , 2007, Molecular Pharmacology.

[34]  S. Tonegawa,et al.  Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice , 2007, Proceedings of the National Academy of Sciences.

[35]  J. Aimone,et al.  Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons , 2007, Neurobiology of Disease.

[36]  C. Shaw,et al.  Lithium Therapy Improves Neurological Function and Hippocampal Dendritic Arborization in a Spinocerebellar Ataxia Type 1 Mouse Model , 2007, PLoS Medicine.

[37]  Wim E. Crusio,et al.  Social behavior deficits in the Fmr1 mutant mouse , 2006, Behavioural Brain Research.

[38]  C. Barnes,et al.  Neural plasticity in the ageing brain , 2006, Nature Reviews Neuroscience.

[39]  M. Tranfaglia,et al.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.

[40]  M. Zhuo,et al.  Deficits in Trace Fear Memory and Long-Term Potentiation in a Mouse Model for Fragile X Syndrome , 2005, The Journal of Neuroscience.

[41]  M. Bear,et al.  Therapeutic implications of the mGluR theory of fragile X mental retardation , 2005, Genes, brain, and behavior.

[42]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[43]  E. Lein,et al.  Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Kirk W. Johnson,et al.  Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. , 2003, Diabetes.

[45]  P. Jin,et al.  New insights into fragile X syndrome: from molecules to neurobehaviors. , 2003, Trends in biochemical sciences.

[46]  R. Malenka,et al.  Beta-catenin is critical for dendritic morphogenesis. , 2003, Nature neuroscience.

[47]  Kirk W. Johnson,et al.  Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. , 2002, Diabetes.

[48]  D. Rubinsztein,et al.  Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation* , 2002, The Journal of Biological Chemistry.

[49]  Karel Svoboda,et al.  Abnormal Development of Dendritic Spines inFMR1 Knock-Out Mice , 2001, The Journal of Neuroscience.

[50]  A. Reith,et al.  Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death , 2001, Journal of neurochemistry.

[51]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[52]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[53]  I. Weiler,et al.  Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Tanouye,et al.  The Drosophila easily shocked gene: A mutation in a phospholipid synthetic pathway causes seizure, neuronal failure, and paralysis , 1994, Cell.

[55]  Guy Nagels,et al.  Fmr1 knockout mice: A model to study fragile X mental retardation , 1994, Cell.

[56]  M. Greenberg,et al.  The regulation and function of c-fos and other immediate early genes in the nervous system , 1990, Neuron.

[57]  W. Rice.  ANALYZING TABLES OF STATISTICAL TESTS , 1989, Evolution; international journal of organic evolution.